Ellence, Epirubicin Newswire

Ellence, Epirubicin Newswire

Comprehensive Real-Time News Feed for Ellence, Epirubicin (generic).

Results 1 - 20 of 29 in Ellence, Epirubicin (generic)

  1. A randomized cross-over trial to detect differences in arm volume...Read the original story w/Photo

    Thursday Jul 21 | BioMed Central

    In an effort to reduce the risk of breast cancer-related arm lymphedema, patients are commonly advised to avoid heavy lifting, impacting activities of daily living and resistance exercise prescription. This advice lacks evidence, with no prospective studies investigating arm volume changes after resistance exercise with heavy loads in this population.

    Comment?

  2. Amgen and Allergan Report Progress in Herceptin Biosimilar Clinical TrialRead the original story w/Photo

    Friday | JD Supra

    In the late 1980's, Dennis Slamon discovered a new oncogene, Her2/neu,that was amplified in 25-33% of human breast cancers. Slamon et al ., " Studies of the HER2/neu ProtoOncogene in Human Breast and Ovarian Cancer ," Science 244: 707-12 .

    Comment?

  3. Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patientsRead the original story w/Photo

    Monday Jul 4 | Medical News

    Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "The rationale of postoperative chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

    Comment?

  4. Chemoradiotherapy after surgery for gastric cancer shows similar...Read the original story w/Photo

    Friday Jul 1 | Medical News Today

    Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "The rationale of postoperative chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

    Comment?

  5. Chemoradiotherapy after surgery for GC shows similar outcomes to post-operative chemotherapyRead the original story w/Photo

    Wednesday Jun 29 | EurekAlert!

    Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "The rationale of postoperative chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

    Comment?

  6. ASCO2016: GANYMED Pharmaceuticals AG's IMAB362 Extends Survival In Gastric CancerRead the original story

    Jun 5, 2016 | BioSpace

    IMAB362 nearly doubles survival in patients with the highest levels of Claudin18.2 target MAINZ, Germany, June 5, 2016 /PRNewswire/ -- Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced outstanding data from its randomized Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting. IMAB362 is a first-in-class monoclonal antibody targeting the cell surface molecule Claudin18.2. The Phase II study in patients with advanced biomarker-positive gastric cancer reached all its endpoints.

    Comment?

  7. Ganymeda s IMAB362 Extends Survival in Gastric CancerRead the original story

    Jun 5, 2016 | Freshnews

    Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced outstanding data from its randomized Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting. IMAB362 is a first-in-class monoclonal antibody targeting the cell surface molecule Claudin18.2. The Phase II study in patients with advanced biomarker-positive gastric cancer reached all its endpoints.

    Comment?

  8. High XIST and Low 53BP1 Expression Predict Poor Outcome after...Read the original story

    May 24, 2016 | CiteULike

    Molecular Cancer Therapeutics , Vol. 15, No. 1. , pp. 190-198, doi:10.1158/1535-7163.mct-15-0470 In previous studies, high expression of XIST and low expression of 53BP1 were respectively associated with poor systemic therapy outcome in patients and therapy resistance in BRCA1-deficient mouse tumor models, but have not been evaluated in BRCA1-deficient patients.

    Comment?

  9. DECT trial shows combination of epirubicin and trastuzumab improves...Read the original story w/Photo

    May 23, 2016 | Medical News

    The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial" has recently appeared in the Journal of Cell Physiology , an international, per-reviewed journal focused on cancer-related issues.

    Comment?

  10. Concurrent Administration of Antrhacyclines and Trastuzumab in Breast ...Read the original story

    May 20, 2016 | Newswise

    Philadelphia-Rome, USA-ITALY May 2016. The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

    Comment?

  11. Ganymed to Present Exciting Phase II Clinical Data for IMAB362 in...Read the original story

    May 17, 2016 | B3C

    Ganymed Pharmaceuticals AG , a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced today that it will present promising efficacy and safety data from its Phase IIb clinical study of IMAB362 in gastroesophageal cancer at the upcoming ASCO 2016 Annual Meeting. The late-breaking oral presentation will be made by Dr. Salah-Eddin Al-Batran, Oncologist and director of the Institute of Clinical Cancer Research, Nordwest Hospital, University Cancer Center Frankfurt, Germany and will take place on June 6 at 8:12 AM in Hall B1.

    Comment?

  12. Antitumor Drugs Market to Gain Impetus from Increasing Incidence of CancerRead the original story

    May 12, 2016 | PressReleasePoint

    Transparency Market Research Report Added "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" Albany, New York, USA., May 12, 2016 - - A new research report by Transparency Market Research presents a comprehensive overview as well as an unbiased analysis of the global market for anti-tumor drugs. The study is titled "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019."

    Comment?

  13. Chemotherapy for intracranial ependymoma in adultsRead the original story w/Photo

    Apr 22, 2016 | BioMed Central

    Ependymal tumors in adults are rare, accounting for less than 4 % of primary tumors of the central nervous system in this age group. The low prevalence of intracranial ependymoma in adults limits the ability to perform clinical trials.

    Comment?

  14. Global Anti-Tumor Drugs Market to Gain Impetus from Increasing Incidence of CancerRead the original story w/Photo

    Mar 28, 2016 | SBWire

    A new research report by Transparency Market Research presents a comprehensive overview as well as an unbiased analysis of the global market for anti-tumor drugs. The study is titled "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019."

    Comment?

  15. Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapyRead the original story w/Photo

    Mar 11, 2016 | Medical News

    Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis. New results from the West German Study Group phase III PlanB trial, presented at the 10th European Breast Cancer Conference today , showed that 94% of women who had been assessed as at low risk of a recurrence of their disease by the 21-gene Recurrence Score test were disease-free after five years.

    Comment?

  16. Multi-gene Test Identifies Early Breast Cancer Patients Who Can Be Spared ChemoRead the original story

    Mar 11, 2016 | Scientific Blogging

    Amsterdam, The Netherlands: Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis. New results from the West German Study Group phase III PlanB trial, presented at the 10th European Breast Cancer Conference today , showed that 94% of women who had been assessed as at low risk of a recurrence of their disease by the 21-gene Recurrence Score test were disease-free after five years.

    Comment?

  17. RNA disruption is associated with response to multiple classes of...Read the original story

    Feb 23, 2016 | BioMed Central

    Cellular stressors and apoptosis-inducing agents have been shown to induce ribosomal RNA degradation in eukaryotic cells. Recently, RNA degradation in vivo was observed in patients with locally advanced breast cancer, where mid-treatment tumor RNA degradation was associated with complete tumor destruction and enhanced patient survival.

    Comment?

  18. Genetic variability in the multidrug resistance associated protein-1...Read the original story

    Feb 24, 2016 | CiteULike

    Genetic variability in the multidrug resistance associated protein-1 predicts hematological toxicity in breast cancer patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide . To assess the impact of single-nucleotide polymorphisms on predefined severe adverse events in breast cancer patients receiving adjuvant 5-fluorouracil , epirubicin and cyclophosphamide chemotherapy.

    Comment?

  19. Epirubicin Industry 2016 Global and Chinese Market Research ReportRead the original story

    Jan 28, 2016 | Emailwire.com

    WiseGuyReports.com adds 'Global and Chinese Epirubicin Industry, 2016 Market Research Report' new report to its research database. The report spread across 150 pages with table and figures.

    Comment?

  20. Breast cancer study suggests new potential drug targets and combinationsRead the original story w/Photo

    Jan 15, 2016 | Medical News Today

    The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations. The authors say the study results, published online January 14 in the journal Cell , will be seized on by labs worldwide to identify new drug candidates in other kinds of cancer , as well to pinpoint mechanisms by which cancer cells resist treatment.

    Comment?